Cite
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
MLA
Johnson, S., et al. “Multicentre Prospective Randomised Trial of Fludarabine versus Cyclophosphamide, Doxorubicin, and Prednisone (CAP) for Treatment of Advanced-Stage Chronic Lymphocytic Leukaemia. The French Cooperative Group on CLL.” Lancet (London, England), vol. 347, no. 9013, May 1996, pp. 1432–38. EBSCOhost, https://doi.org/10.1016/s0140-6736(96)91681-5.
APA
Johnson, S., Smith, A. G., Löffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P. J., & Hiddemann, W. (1996). Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet (London, England), 347(9013), 1432–1438. https://doi.org/10.1016/s0140-6736(96)91681-5
Chicago
Johnson, S, A G Smith, H Löffler, E Osby, G Juliusson, B Emmerich, P J Wyld, and W Hiddemann. 1996. “Multicentre Prospective Randomised Trial of Fludarabine versus Cyclophosphamide, Doxorubicin, and Prednisone (CAP) for Treatment of Advanced-Stage Chronic Lymphocytic Leukaemia. The French Cooperative Group on CLL.” Lancet (London, England) 347 (9013): 1432–38. doi:10.1016/s0140-6736(96)91681-5.